Table 2.

Baseline clinical characteristics of patients at the time of biopsy and at the end of follow-up, compared to the original Oxford study

All Patients (n = 410)Oxford Cohort (n = 265) 8
At time of biopsy
    Age (yrs)31 ± 10.830 (4–73)
    Female (%)51.0%28%
    MAP (mmHg)94.0 ± 14.298 ± 17
    eGFR (ml/min per 1.73 m2)85.8 ± 28.183 ± 36
    Proteinuria (g/d)1.7 (0.5 to 21.8)1.7 (0.5 to 18.5)
    Stage 1, 2, 3 (K-DOQI)(%)43, 38, 19%36, 38, 26%
Follow-up
    duration of follow-up (months)38 (12 to 171)69 (12 to 268)
    treated with RAS blockade (ACEi/ARB) (%)86.1%74%
    treated with immunosuppressant (%)20.0%9%
    treated with prednisone (%)42.7%29%
    ESRD (%)7.3%13%
  • eGFR, estimated GFR; MAP, mean arterial pressure; RAS, renin angiotensin system; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; ESRD, end-stage renal disease defined as eGFR <15 ml/min per 1.73 m2 or renal replacement therapy. K-DOQI, Kidney Disease Outcomes Quality Initiative.